Andrés Vásquez-Domínguez

Andrés Vásquez-Domínguez

Auto-generated profile, based on publicly available information

Andrés Vásquez-Domínguez

Dirección de Laboratorio de Salud Pública, Dirección Regional de Salud Callao. Callao, Perú

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2018 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
RPRosa Palacios-Salvatierra
Rosa Palacios-Salvatierra
OCOmar Cáceres-Rey
Omar Cáceres-Rey
AVAndrés Vásquez-Domínguez
Andrés Vásquez-Domínguez
PMPatricia Mosquera-Visaloth
Patricia Mosquera-Visaloth
EAElizabeth Anaya-Ramírez
Elizabeth Anaya-Ramírez
Especies rickettsiales en casos humanos con síndrome febril agudo inespecífico en Perú

Verified
Journal Article
Open access
PDF file
LJLuis Jose Jaramillo-Valverde
Luis Jose Jaramillo-Valverde
KLKelly S Levano
Kelly S Levano
DTDavid Tarazona
David Tarazona
AVAndres Vasquez-Dominguez
Andres Vasquez-Dominguez
ATAnel Toledo-Nauto
Anel Toledo-Nauto
HGHEINNER GUIO
HEINNER GUIO
In Peru, 24,581 people were diagnosed with tuberculosis (TB) in 2020. Although TB treatments are effective, 3.4–13% are associated with significant adverse drug reactions (ADRs), with drug-induced liver injury (DILI) considered the most predominant. Among the first-line antituberculosis drugs, isoniazid (INH) is the main drug responsible for the appearance of DILI. In the liver, INH is metabolized by the enzymes N-acetyltransferase-2 (NAT2), cytochrome P450 2E1 (CYP2E1), and glutathione S-transferase (GST) with two isoforms, GSTT1 and GSTM1. Based on previous studies, we hypothesized that interactions between the GSTT1 and GSTM1 null genotypes induce DILI in TB patients. In this cross-sectional study of 377 participants who completed their anti-TB treatment, we genotyped by revealing the presence or absence of 215- and 480-bp bands of GSTM1 and GSTT1, respectively. We found that the prevalence of the GSTM1 genotype was 52.79% and 47.21% for presence and null, respectively, and for GSTT1 it was 69.76% and 30.24% for presence and null, respectively. Neither genotype was prevalent in the patients who developed DILI (n = 16). We did not confirm our hypothesis; however, we found that the combination of GSTM1 present genotype, GSTT1 null genotype, fast NAT2 acetylators, and CYP2E1 c1/c1 genotype had a significant risk for the development of ADR (OR 11; p = 0.017; 95% CI: (0.54–186.35)). We propose that the presence of the GSTM1 present genotype, GSTT1 null genotype, fast NAT2 acetylators, and CYP2E1 c1/c1 genotype in the Peruvian population could be considered a risk factor for the development of ADR due to therapeutic drug intake.

28 September 2026 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
EMEduardo Miranda-Ulloa
Eduardo Miranda-Ulloa
SRSoledad Romero-Ruiz
Soledad Romero-Ruiz
RBRonal Briceño-Espinoza
Ronal Briceño-Espinoza
AVAndrés Vásquez-Domínguez
Andrés Vásquez-Domínguez
DSDilan Suárez-Agüero
Dilan Suárez-Agüero
Esta investigación planteó determinar el rendimiento de un western blot (WB) dual in house para la detección individual y simultánea de anticuerpos anti-HTLV-1 y anti-VIH-1; la tira se diseñó con antígeno HTLV-1 (1,67ug/mm) arriba y VIH-1 (1,34 ug/mm) abajo. Se evaluó el WB dual in house con 260 sueros referentes procedentes de una seroteca: 50 HTLV-1/VIH-1 positivos, 50 VIH-1 positivos, 60 HTLV-1 positivos, 50 negativos y 50 interferentes. La precisión se evaluó en cinco regiones del Perú. Se obtuvo una sensibilidad y especificidad general de 96,3% (IC 95%: 93,0‒99,5) y 100% (IC 95%: 99,5‒100,0), respectivamente. Individualmente, la sensibilidad fue del 94% en coinfectados HTLV-1/VIH-1, 96,7% en HTLV-1 y 98% en VIH-1. La repetibilidad y reproducibilidad fue del 100% en condiciones de 34‒ 3256 m s. n. m., 16,4‒37,9 °C y 42‒95% de humedad relativa. Concluimos que el WB dual in house HTLV-1/VIH-1 presenta alto rendimiento diagnóstico.

25 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
AVAndrés Vásquez-Domínguez
Andrés Vásquez-Domínguez
LJLuis Jose Jaramillo-Valverde
Luis Jose Jaramillo-Valverde
KLKelly S Levano
Kelly S Levano
PNPedro Novoa-Bellota
Pedro Novoa-Bellota
MMMarco Machaguay-Romero
Marco Machaguay-Romero
HGHEINNER GUIO
HEINNER GUIO
Genetic and microbiome studies of ancient Caral-Supe civilization have not yet been published. For this reason, the objective of this work is to identify the microorganisms and possible diseases that existed in this ancient civilization using coprolites samples. To do this, two coprolites samples were analyzing through high-throughput sequencing data of 16S rRNA gene and an intergenic region (ITS).

10 April 2023 in Revista Médica Herediana
Verified
Journal Article
Open access
PDF file
AVAndrés Vásquez-Domínguez
Andrés Vásquez-Domínguez
WCWilliam Cassa-Loaiza
William Cassa-Loaiza
CVCinthya Vásquez-Velásquez
Cinthya Vásquez-Velásquez
KÁKeyla Álvarez-Huambachano
Keyla Álvarez-Huambachano
Gustavo F. GonzalesGustavo F. Gonzales
Gustavo F. Gonzales